Axsome Therapeutics Inc. (AXSM)

NasdaqGM: AXSM · Real-Time Price · USD

208.03

-10.17 (-4.66%)

At close: Aug 21, 2026, 12:47 PM

The price, the headline numbers and the latest news, in one place.

-4.66% (1D)

Bid	170.52
Market Cap	10.96B
Revenue (ttm)	776.57M
Net Income (ttm)	-191.64M
	0.73
	-3.75
	n/a
	41.57
P/B (ttm)	131.36
P/S (ttm)	14.11
Earnings Date	Nov 2, 2026

Ask	259.2
Volume	620,864
Avg. Volume (20D)	873,135
Open	216.50
Previous Close	218.20
Day's Range	206.25 - 217.15
52-Week Range	112.90 - 260.19
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (so...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 19, 2015

Employees 1,346

Stock Exchange NasdaqGM

Ticker Symbol AXSM

Website https://www.axsome.com

Full Company Profile

Financial Performance

In 2025, Axsome Therapeutics's revenue was 638.5M, an increase of 65.55% compared to the previous year's 385.69M. Earnings were -183.17M, a decrease of -36.22%.

Financial Statements

Earnings Surprise

Axsome Therapeutics has released their quarterly earnings on Aug 10, 2026:

Revenue of $191.2M misses estimates by $0, with 57.42% YoY growth.

EPS of -0.99 misses estimates by -0.21, with -2.06% YoY decline.

Next Earnings Release

Axsome Therapeutics Inc. is scheduled to release its earnings on Nov 2, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Zacks

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

1 week ago · Simply Wall St.

Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now?

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnin...

1 week ago · Simply Wall St.

Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price?

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the ...